Implant Sciences to Receive U.S. Patent on Explosive Detection System; Receives Final Approval from U.S. Patent and Trademark Office

WAKEFIELD, Mass.--Aug. 23, 2004
Implant Sciences Corporation (AMEX: "IMX", "IMX.WS"), a developer and manufacturer of products for national security, medicine and industry, has received complete and final approval on a patent application for its new explosives detection technology. The company has paid all appropriate fees and expects the U.S. Patent and Trademark Office to issue the patent within the next few weeks.

The patent, applied for January 22, 2003, covers the explosives detection system contained in both the Company's battery-powered hand-held device and the bench-top equipment. One of the critical innovations covered by the new patent is the technology involved in heating and acquiring the input air using a cyclone sampling nozzle.

Dr. Anthony J. Armini, Chairman and CEO of Implant Sciences stated, "Although we have five (5) other applications to the patent office pending, each on different aspects of our explosives detection technology, this is perhaps the most important one because it protects our claim to the overall system design. This new patent also confirms the uniqueness of our design and adds to the credibility of our new explosives detection technology with our potential customers."

About Implant Sciences

Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for national security, medicine, and industry. Under development are portable and bench-top trace element detection devices to identify explosives, narcotics and other toxic materials. The Company has also received government grants from the US Army, Navy and Air Force, and the Transportation Security Administration to adapt the Company's explosive detection technology to a wide number of security requirements.

Using its proprietary ion implantation and thin film coating technologies, Implant Sciences has a sophisticated production line that modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby substantially increasing the life of the implants. The company also manufactures and markets radioactive and non-radioactive products for medical use, including radioactive seeds for treating prostate cancer that are distributed throughout the United States by its own direct sales force. In parallel with the production of these seeds, it is also developing additional brachytherapy products for the treatment of breast, eye, and other cancers.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.